<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565615</url>
  </required_header>
  <id_info>
    <org_study_id>A2581197</org_study_id>
    <nct_id>NCT02565615</nct_id>
  </id_info>
  <brief_title>Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting</brief_title>
  <acronym>ATTENTION</acronym>
  <official_title>ATORVASTATIN EFFECTIVENESS AND SAFETY IN CARDIOLOGY PATIENTS IN REAL WORLD SETTING: A REGISTRY STUDY IN CHINA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to verify atorvastatin effectiveness and safety in Chinese population, and
      explore the optimal atorvastatin regimens in high-to-moderate risk for ASCVD。
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 22, 2016</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Weeks</target_duration>
  <primary_outcome>
    <measure>Achievement Rate for Low Density Lipoprotein-Cholesterol (LDL-C) for Overall</measure>
    <time_frame>12 weeks</time_frame>
    <description>Achievement Rate was defined as ratio of number of participants who achieved LDL-C target value to number of participants who completed 12-week follow up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Achievement Rate for LDL-C by Dose Group Within Each Cardiovascular Disease (CVD) Risk Level</measure>
    <time_frame>12 weeks</time_frame>
    <description>Achievement Rate was defined as ratio of number of participants who achieved LDL-C target value to number of participants who completed 12-week follow up according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Lipid Parameters at Week 12 for Overall</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG). The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline data was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline for Lipid Parameters at Week 12 for Overall</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG). The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Percent change from baseline was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Lipid Parameters at Week 12 Within Each CVD Risk Group</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG) according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes. The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline data was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline for Lipid Parameters at Week 12 Within Each CVD Risk Level</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG) according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes. The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Percent change from baseline was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Drug Exposure for Overall - Total Dose and Week 12 Dose</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>Atorvastatin total dose: calculated from Day 1 to Week 12 or last dose day; Week 12 dose: dose taken at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Drug Exposure for Overall - Daily Dose</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>Daily dose was calculated by total dose divided by the total days of receiving atorvastatin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Drug Exposure Within Each CVD Risk Group - Total Dose and Week 12 Dose</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>Atorvastatin total dose: calculated from Day 1 to Week 12 or last dose; Week 12 dose: dose taken at Week 12 according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Drug Exposure Within Each CVD Risk Group -Daily Dose</measure>
    <time_frame>Day 1 to Week 12</time_frame>
    <description>Daily dose was calculated by total dose divided by the total days of receiving atorvastatin according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-related) for Overall</measure>
    <time_frame>Baseline to Week 12 (±28 days) or any unplanned visit (if occurred: any date during Week 4 to Week 16 )</time_frame>
    <description>All causalities adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage; Treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-related) by Dose Group Within Each CVD Risk Level</measure>
    <time_frame>Baseline to Week 12 (±28 days) or any unplanned visit (if occurred: any date during Week 4 to Week 16 )</time_frame>
    <description>All causalities adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage; Treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage. The AEs were categorized by the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events of Special Interest (AESI) for Overall</measure>
    <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred:any date during Week 4 to Week 16)</time_frame>
    <description>AESI were categorized as muscle symptoms: myalgia, fatigue, weakness, creatine kinase (CK) values 10 times the upper limit of normal, or rhabdomyolysis, and muscle damage based on significant elevated CK; major cardiovascular events: myocardial infarction, stroke, unstable angina requiring re-hospitalization, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting; Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events of Special Interest (AESI) by Dose Group Within Each CVD Risk Level</measure>
    <time_frame>Baseline (Day 1) to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
    <description>AESI were categorized as muscle symptoms: myalgia, fatigue, weakness, creatine kinase (CK) values 10 times the upper limit of normal, or rhabdomyolysis, and muscle damage based on significant elevated CK; major cardiovascular events: myocardial infarction, stroke, unstable angina requiring re-hospitalization, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting; Death according to the CVD risk stratification. Low-risk: 10 years CV risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Elevated Abnormal Laboratory in Creatine Kinanse (CK), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) for Overall</measure>
    <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
    <description>The elevated abnormal laboratory data was summarized: significant elevated CK: CK values 10 times the upper limit of normal; Persistent elevation in alanine aminotransferase, aspartate aminotransferase, or both: 2 consecutive measurements obtained 4 to 10 days apart that was more than 3 times the upper limit of the normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Elevated Abnormal Laboratory in CK, ALT and AST by Dose Group Within Each CVD Risk</measure>
    <time_frame>Baseline to Week 12 (±28 days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
    <description>The elevated abnormal laboratory data was summarized: significant elevated CK: CK values 10 times the upper limit of normal; Persistent elevation in alanine aminotransferase, aspartate aminotransferase, or both: 2 consecutive measurements obtained 4 to 10 days apart that was more than 3 times the upper limit of the normal range according to the CVD risk stratification. Low-risk: 10 years CV risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Clinical Laboratory Overall- ALT and AST</measure>
    <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
    <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for ALT and AST date were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Clinical Laboratory Overall- Bilirubin, Blood Urea Nitrogen, Cholesterol, Creatinine, Triglycerides, Uric Acid</measure>
    <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
    <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline for bilirubin, blood urea nitrogen, cholesterol (total), creatinine, triglycerides, uric acid data were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Clinical Laboratory Overall- Creatine Kinase</measure>
    <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
    <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for creatine kinase was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Clinical Laboratory by Dose Group Within Each CVD Risk Level-ALT and AST</measure>
    <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred:any date during Week 4 to Week 16)</time_frame>
    <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for ALT and AST date were reported according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Clinical Laboratory by Dose Group Within Each CVD Risk Level- Bilirubin, Blood Urea Nitrogen, Cholesterol, Creatinine, Triglycerides, Uric Acid</measure>
    <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
    <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline for bilirubin, blood urea nitrogen, cholesterol (total), creatinine, triglycerides, uric acid data were reported according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Clinical Laboratory by Dose Group Within Each CVD Risk Level- Creatine Kinase</measure>
    <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
    <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for creatine kinase was reported according to the CVD risk stratification. Low-risk: 10 years CV risk &lt;5%; Moderate-risk: 10 years CVD risk 5%~10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10%~15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Precentage of Participants With Discontinuation From the Study for Overall</measure>
    <time_frame>12 weeks of follow-up</time_frame>
    <description>Percentage of participants who dropped out of the study and reasons for discontinuation were summarized overall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Precentage of Participants With Discontinuation From the Study by Dose Group Within Each CVD Risk Level</measure>
    <time_frame>12 weeks of follow-up</time_frame>
    <description>Percentage of participants who dropped out of the study and reasons for discontinuation were summarized by the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5115</enrollment>
  <condition>Coronary Artery Disease, Hypercholesterolemia, Hypertension</condition>
  <arm_group>
    <arm_group_label>Atorvastatin dose titration (single-arm)</arm_group_label>
    <description>Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Because this is a non-interventional study, there is no intervention here.</description>
    <arm_group_label>Atorvastatin dose titration (single-arm)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese cardiology patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged ≥18 years;

          -  Cardiology patients who has been prescribed atorvastatin by physician's clinical
             judgment under normal clinical care. These patients will include those with
             established coronary heart disease, or having multiple risk factors and at risk for
             cardiovascular disease, or primary hypercholesterolemia.

          -  Baseline laboratory reports prior to starting atorvastatin therapy can be tracked ,
             including lipid measurement, liver function, and Creatine Kinase (CK) value. The date
             of baseline reports should be within 1 month before taking atorvastatin or within 24h
             after starting atorvastatin therapy.

          -  Evidence of a personally or his/her legally acceptable representative signed and dated
             informed consent document indicating that the patient has been informed of all
             pertinent aspects of the study and accept follow-up visit.

        Exclusion Criteria:

          -  Patients who have regularly taken atorvastatin therapy more than 4 weeks before
             enrollment

          -  Concomitant any other lipid-lower medication at baseline, or during the study
             conduction on physician clinical judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First People's Hospital of Fuyang City</name>
      <address>
        <city>Fuyang</city>
        <state>Anhui</state>
        <zip>236000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Meitan General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100028</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHINA-JAPAN Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fu Xing Hospital Affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NAVY General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guang'anmen hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Fangshan District , Beijing</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102400</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Beijing Daxing District</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102600</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Meitan General Hospital</name>
      <address>
        <city>Biejing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing Dianjiang People's Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yongchuan hospital of chongqing medical university</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>402160</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chongqing Wanzhou People's Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuling center hospital of chongqing city</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>408000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiamen Cardiovascular Hospital</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shunde people's Hospital</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510580</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangmen Central Hospital</name>
      <address>
        <city>Jiangmen</city>
        <state>Guangdong</state>
        <zip>529000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhuhai People's Hospital</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heilongjiang Provincial Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Peoples Hspital of Hebi City</name>
      <address>
        <city>Hebi</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiaozuo City Second People's Hospital</name>
      <address>
        <city>Jiaozuo</city>
        <state>Henan</state>
        <zip>454001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puyang Oilfield General Hosipital</name>
      <address>
        <city>Puyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of henan university of TCM</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhengzhou No. 7 People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan University - Renmin Hospital (Hubei General Hospital)</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangning People's Hospital</name>
      <address>
        <city>Nanjing,</city>
        <state>Jiangsu China</state>
        <zip>211100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Provincial Hospital of Jiangsu Province</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu,china</state>
        <zip>210024</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huai'An First People's Hospital</name>
      <address>
        <city>Huaian</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Taizhou People's Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Jiangsu</state>
        <zip>225300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Jiangsu People's Hospital</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing colleague hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu，china</state>
        <zip>211102</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 2nd hospital of Nanchang university</name>
      <address>
        <city>NanChang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Shenyang Military</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Red Cross Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Nanjing, Jiangsu</state>
        <zip>210001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ji'nan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai University of Traditional Chinese Medicine affiliated Yueyang Hospital of traditional Chine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai，china</state>
        <zip>200082</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Cardiovascular Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030024</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The first people's Hospital of Xiaoshan District</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang China</state>
        <zip>311200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lanxi Municipal People's Hospital</name>
      <address>
        <city>Lanxi</city>
        <state>Zhejiangchina</state>
        <zip>321100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongyang People's Hospital</name>
      <address>
        <city>Jinhua</city>
        <state>Zhejiang</state>
        <zip>322100</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ningbo First Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Medical College of Ningbo University</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quzhou Hospital of Zhejiang University</name>
      <address>
        <city>Quzhou</city>
        <state>Zhejiang</state>
        <zip>324000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruian People's Hospital</name>
      <address>
        <city>Ruian</city>
        <state>Zhejiang</state>
        <zip>325200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital attached to aeromedicine institute of P.L.A (466 Hospital)</name>
      <address>
        <city>Beijing</city>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Yangpu District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Minhang District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>201111</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A2581197</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <results_first_submitted>August 14, 2019</results_first_submitted>
  <results_first_submitted_qc>October 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2019</results_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02565615/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02565615/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin &lt;=10 mg</title>
          <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin 20 mg</title>
          <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="P3">
          <title>Atorvastatin 30 mg</title>
          <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="P4">
          <title>Atorvastatin 40 mg</title>
          <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="P5">
          <title>Atorvastatin Unknown Dosage</title>
          <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="291"/>
                <participants group_id="P2" count="3080"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="101"/>
                <participants group_id="P5" count="1622"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="291"/>
                <participants group_id="P2" count="3080"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="101"/>
                <participants group_id="P5" count="1055"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="288"/>
                <participants group_id="P2" count="3044"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="98"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1601"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not willing to participate in study</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="169"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="765"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not meeting eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not defined</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="62"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Untreated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="567"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Included all enrolled participants who received at least 1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin &lt;=10 mg</title>
          <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin 20 mg</title>
          <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="B3">
          <title>Atorvastatin 30 mg</title>
          <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="B4">
          <title>Atorvastatin 40 mg</title>
          <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="B5">
          <title>Atorvastatin Unknown Dosage</title>
          <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="291"/>
            <count group_id="B2" value="3080"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="101"/>
            <count group_id="B5" value="1055"/>
            <count group_id="B6" value="4548"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="291"/>
                    <count group_id="B2" value="3080"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="101"/>
                    <count group_id="B5" value="1055"/>
                    <count group_id="B6" value="4548"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="12.0"/>
                    <measurement group_id="B2" value="61.3" spread="11.6"/>
                    <measurement group_id="B3" value="59.5" spread="8.4"/>
                    <measurement group_id="B4" value="63.2" spread="11.3"/>
                    <measurement group_id="B5" value="62.2" spread="12.3"/>
                    <measurement group_id="B6" value="61.7" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="291"/>
                    <count group_id="B2" value="3080"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="101"/>
                    <count group_id="B5" value="1055"/>
                    <count group_id="B6" value="4548"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="1390"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="483"/>
                    <measurement group_id="B6" value="2067"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="1690"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="572"/>
                    <measurement group_id="B6" value="2481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Included participants with non-missing values</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="282"/>
                    <count group_id="B2" value="3029"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="98"/>
                    <count group_id="B5" value="1026"/>
                    <count group_id="B6" value="4456"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="11.0"/>
                    <measurement group_id="B2" value="67.9" spread="11.8"/>
                    <measurement group_id="B3" value="68.6" spread="8.2"/>
                    <measurement group_id="B4" value="67.5" spread="11.4"/>
                    <measurement group_id="B5" value="66.0" spread="12.2"/>
                    <measurement group_id="B6" value="67.3" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Included participants with non-missing values</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="282"/>
                    <count group_id="B2" value="3035"/>
                    <count group_id="B3" value="21"/>
                    <count group_id="B4" value="98"/>
                    <count group_id="B5" value="1024"/>
                    <count group_id="B6" value="4460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163.3" spread="7.8"/>
                    <measurement group_id="B2" value="164.6" spread="7.8"/>
                    <measurement group_id="B3" value="166.0" spread="6.9"/>
                    <measurement group_id="B4" value="163.8" spread="8.4"/>
                    <measurement group_id="B5" value="164.1" spread="7.7"/>
                    <measurement group_id="B6" value="164.4" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Achievement Rate for Low Density Lipoprotein-Cholesterol (LDL-C) for Overall</title>
        <description>Achievement Rate was defined as ratio of number of participants who achieved LDL-C target value to number of participants who completed 12-week follow up.</description>
        <time_frame>12 weeks</time_frame>
        <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement Rate for Low Density Lipoprotein-Cholesterol (LDL-C) for Overall</title>
          <description>Achievement Rate was defined as ratio of number of participants who achieved LDL-C target value to number of participants who completed 12-week follow up.</description>
          <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria.</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="1445"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" lower_limit="0.716" upper_limit="0.857"/>
                    <measurement group_id="O2" value="0.67" lower_limit="0.640" upper_limit="0.690"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.359" upper_limit="0.996"/>
                    <measurement group_id="O4" value="0.57" lower_limit="0.432" upper_limit="0.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Achievement Rate for LDL-C by Dose Group Within Each Cardiovascular Disease (CVD) Risk Level</title>
        <description>Achievement Rate was defined as ratio of number of participants who achieved LDL-C target value to number of participants who completed 12-week follow up according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
        <time_frame>12 weeks</time_frame>
        <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement Rate for LDL-C by Dose Group Within Each Cardiovascular Disease (CVD) Risk Level</title>
          <description>Achievement Rate was defined as ratio of number of participants who achieved LDL-C target value to number of participants who completed 12-week follow up according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
          <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="1445"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="129"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.735" upper_limit="1.000"/>
                    <measurement group_id="O2" value="0.93" lower_limit="0.870" upper_limit="0.967"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.158" upper_limit="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.839" upper_limit="1.000"/>
                    <measurement group_id="O2" value="0.89" lower_limit="0.827" upper_limit="0.936"/>
                    <measurement group_id="O4" value="0.78" lower_limit="0.400" upper_limit="0.972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="733"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.671" upper_limit="0.855"/>
                    <measurement group_id="O2" value="0.68" lower_limit="0.649" upper_limit="0.718"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.359" upper_limit="0.996"/>
                    <measurement group_id="O4" value="0.56" lower_limit="0.349" upper_limit="0.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very High risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="438"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.289" upper_limit="0.756"/>
                    <measurement group_id="O2" value="0.48" lower_limit="0.432" upper_limit="0.529"/>
                    <measurement group_id="O4" value="0.45" lower_limit="0.244" upper_limit="0.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Lipid Parameters at Week 12 for Overall</title>
        <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG). The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline data was reported.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Lipid Parameters at Week 12 for Overall</title>
          <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG). The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline data was reported.</description>
          <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>milligram/deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="1445"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="1410"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.81" spread="43.971"/>
                    <measurement group_id="O2" value="-45.12" spread="394.177"/>
                    <measurement group_id="O3" value="-40.35" spread="44.527"/>
                    <measurement group_id="O4" value="-36.98" spread="54.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (HDL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="1409"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="10.619"/>
                    <measurement group_id="O2" value="0.44" spread="13.643"/>
                    <measurement group_id="O3" value="0.13" spread="7.421"/>
                    <measurement group_id="O4" value="-0.17" spread="8.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (LDL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="1407"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.26" spread="35.375"/>
                    <measurement group_id="O2" value="-31.47" spread="38.285"/>
                    <measurement group_id="O3" value="-31.40" spread="34.152"/>
                    <measurement group_id="O4" value="-36.00" spread="40.783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="1409"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.69" spread="94.228"/>
                    <measurement group_id="O2" value="-27.55" spread="107.785"/>
                    <measurement group_id="O3" value="-83.19" spread="151.512"/>
                    <measurement group_id="O4" value="-20.97" spread="160.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline for Lipid Parameters at Week 12 for Overall</title>
        <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG). The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Percent change from baseline was reported.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline for Lipid Parameters at Week 12 for Overall</title>
          <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG). The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Percent change from baseline was reported.</description>
          <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>Percent Change (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="1445"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="1410"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.96" spread="24.219"/>
                    <measurement group_id="O2" value="-13.66" spread="34.091"/>
                    <measurement group_id="O3" value="-17.33" spread="19.989"/>
                    <measurement group_id="O4" value="-3.07" spread="104.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (HDL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="1409"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" spread="26.013"/>
                    <measurement group_id="O2" value="4.18" spread="25.386"/>
                    <measurement group_id="O3" value="1.52" spread="15.985"/>
                    <measurement group_id="O4" value="0.91" spread="15.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (LDL)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="1407"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.40" spread="32.437"/>
                    <measurement group_id="O2" value="-20.11" spread="50.643"/>
                    <measurement group_id="O3" value="-22.57" spread="26.524"/>
                    <measurement group_id="O4" value="-23.68" spread="25.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="1409"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.03" spread="82.582"/>
                    <measurement group_id="O2" value="-4.04" spread="52.636"/>
                    <measurement group_id="O3" value="-27.55" spread="33.921"/>
                    <measurement group_id="O4" value="-12.33" spread="34.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Lipid Parameters at Week 12 Within Each CVD Risk Group</title>
        <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG) according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes. The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline data was reported.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Lipid Parameters at Week 12 Within Each CVD Risk Group</title>
          <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG) according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes. The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline data was reported.</description>
          <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="1445"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol-Low risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.42" spread="42.967"/>
                    <measurement group_id="O2" value="-47.99" spread="56.938"/>
                    <measurement group_id="O4" value="-94.98" spread="71.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol-Moderate risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.97" spread="42.807"/>
                    <measurement group_id="O2" value="-43.23" spread="49.231"/>
                    <measurement group_id="O4" value="-5.28" spread="61.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol- High risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="711"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.04" spread="43.996"/>
                    <measurement group_id="O2" value="-56.59" spread="552.696"/>
                    <measurement group_id="O3" value="-40.35" spread="44.527"/>
                    <measurement group_id="O4" value="-38.43" spread="49.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol- Very high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="426"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="31.528"/>
                    <measurement group_id="O2" value="-25.78" spread="49.060"/>
                    <measurement group_id="O4" value="-43.16" spread="51.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (HDL)- Low risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="8.445"/>
                    <measurement group_id="O2" value="-1.80" spread="9.943"/>
                    <measurement group_id="O4" value="-8.30" spread="24.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (HDL)- Moderate risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="10.964"/>
                    <measurement group_id="O2" value="-0.92" spread="10.398"/>
                    <measurement group_id="O4" value="5.06" spread="10.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (HDL)- High risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="711"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="11.112"/>
                    <measurement group_id="O2" value="0.64" spread="14.169"/>
                    <measurement group_id="O3" value="0.13" spread="7.421"/>
                    <measurement group_id="O4" value="1.21" spread="5.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (HDL)- Very high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="9.675"/>
                    <measurement group_id="O2" value="1.25" spread="14.585"/>
                    <measurement group_id="O4" value="-3.02" spread="7.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (LDL)- Low risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.29" spread="37.689"/>
                    <measurement group_id="O2" value="-42.37" spread="37.719"/>
                    <measurement group_id="O4" value="-74.71" spread="53.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (LDL)- Moderate risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.07" spread="33.338"/>
                    <measurement group_id="O2" value="-37.50" spread="37.162"/>
                    <measurement group_id="O4" value="-25.91" spread="32.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (LDL)- High risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="710"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.61" spread="35.093"/>
                    <measurement group_id="O2" value="-33.10" spread="39.149"/>
                    <measurement group_id="O3" value="-31.40" spread="34.152"/>
                    <measurement group_id="O4" value="-34.61" spread="44.918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (LDL)- Very high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.99" spread="26.243"/>
                    <measurement group_id="O2" value="-23.41" spread="35.895"/>
                    <measurement group_id="O4" value="-38.05" spread="38.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides- Low risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.92" spread="48.340"/>
                    <measurement group_id="O2" value="-28.67" spread="110.490"/>
                    <measurement group_id="O4" value="-14.16" spread="35.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides- Moderate risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="43.420"/>
                    <measurement group_id="O2" value="-22.32" spread="70.978"/>
                    <measurement group_id="O4" value="-18.19" spread="61.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides- High risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="711"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.85" spread="102.165"/>
                    <measurement group_id="O2" value="-29.73" spread="116.182"/>
                    <measurement group_id="O3" value="-83.19" spread="151.512"/>
                    <measurement group_id="O4" value="-46.98" spread="127.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides- Very high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.34" spread="113.398"/>
                    <measurement group_id="O2" value="-25.34" spread="102.889"/>
                    <measurement group_id="O4" value="4.47" spread="217.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline for Lipid Parameters at Week 12 Within Each CVD Risk Level</title>
        <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG) according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes. The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Percent change from baseline was reported.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline for Lipid Parameters at Week 12 Within Each CVD Risk Level</title>
          <description>Lipid parameters included LDL-C, High-Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol (TC), and Triglycerides (TG) according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes. The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Percent change from baseline was reported.</description>
          <population>The full analysis set (FAS) analysis population included all enrolled in the study that received at least 1 dose of atorvastatin and completed 12- week follow-up. &quot;Atorvastatin Unknown Dosage&quot; arm did not meet FAS criteria. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="1445"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol- low risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.06" spread="18.145"/>
                    <measurement group_id="O2" value="-15.39" spread="53.309"/>
                    <measurement group_id="O4" value="-36.33" spread="23.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol- moderate risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.66" spread="23.157"/>
                    <measurement group_id="O2" value="-18.50" spread="24.651"/>
                    <measurement group_id="O4" value="73.60" spread="253.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol- high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="711"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.53" spread="24.302"/>
                    <measurement group_id="O2" value="-13.91" spread="34.085"/>
                    <measurement group_id="O3" value="-17.33" spread="19.989"/>
                    <measurement group_id="O4" value="-15.34" spread="18.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol- very high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="426"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.09" spread="22.562"/>
                    <measurement group_id="O2" value="-11.07" spread="29.007"/>
                    <measurement group_id="O4" value="-18.58" spread="24.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (HDL) - low risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="15.236"/>
                    <measurement group_id="O2" value="-1.55" spread="17.047"/>
                    <measurement group_id="O4" value="-7.03" spread="35.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (HDL)- moderate risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.08" spread="20.094"/>
                    <measurement group_id="O2" value="0.29" spread="18.265"/>
                    <measurement group_id="O4" value="12.12" spread="22.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (HDL)- high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="711"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="29.176"/>
                    <measurement group_id="O2" value="4.59" spread="25.053"/>
                    <measurement group_id="O3" value="1.52" spread="15.985"/>
                    <measurement group_id="O4" value="2.42" spread="11.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (HDL)- very high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.02" spread="22.796"/>
                    <measurement group_id="O2" value="6.55" spread="29.457"/>
                    <measurement group_id="O4" value="-4.53" spread="13.600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (LDL)- low risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="127"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.33" spread="26.408"/>
                    <measurement group_id="O2" value="-27.43" spread="22.633"/>
                    <measurement group_id="O4" value="-47.37" spread="30.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (LDL)- moderate risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.59" spread="29.052"/>
                    <measurement group_id="O2" value="-27.12" spread="27.917"/>
                    <measurement group_id="O4" value="-20.86" spread="24.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (LDL)- high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="710"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.16" spread="32.501"/>
                    <measurement group_id="O2" value="-21.81" spread="31.964"/>
                    <measurement group_id="O3" value="-22.57" spread="26.524"/>
                    <measurement group_id="O4" value="-20.59" spread="26.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (LDL)- very high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="34.076"/>
                    <measurement group_id="O2" value="-12.68" spread="79.286"/>
                    <measurement group_id="O4" value="-25.92" spread="25.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides- low risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="128"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.40" spread="32.030"/>
                    <measurement group_id="O2" value="-9.65" spread="39.610"/>
                    <measurement group_id="O4" value="-9.63" spread="32.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides- moderate risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.98" spread="40.156"/>
                    <measurement group_id="O2" value="-8.81" spread="39.316"/>
                    <measurement group_id="O4" value="-10.93" spread="37.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides- high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="711"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.35" spread="92.014"/>
                    <measurement group_id="O2" value="-3.77" spread="50.582"/>
                    <measurement group_id="O3" value="-27.55" spread="33.921"/>
                    <measurement group_id="O4" value="-14.81" spread="34.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides- very high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.01" spread="89.326"/>
                    <measurement group_id="O2" value="-1.17" spread="62.412"/>
                    <measurement group_id="O4" value="-10.55" spread="36.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Drug Exposure for Overall - Total Dose and Week 12 Dose</title>
        <description>Atorvastatin total dose: calculated from Day 1 to Week 12 or last dose day; Week 12 dose: dose taken at Week 12</description>
        <time_frame>Day 1 to Week 12</time_frame>
        <population>The analysis set included all participants who received at least 1 dose of atorvastatin. &quot;Atorvastatin Unknown Dosage&quot; did not have Week 12 dose. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin Unknown Dosage</title>
            <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Drug Exposure for Overall - Total Dose and Week 12 Dose</title>
          <description>Atorvastatin total dose: calculated from Day 1 to Week 12 or last dose day; Week 12 dose: dose taken at Week 12</description>
          <population>The analysis set included all participants who received at least 1 dose of atorvastatin. &quot;Atorvastatin Unknown Dosage&quot; did not have Week 12 dose. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="1055"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="3080"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="101"/>
                    <count group_id="O5" value="845"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="958.90" spread="240.812"/>
                    <measurement group_id="O2" value="1816.63" spread="376.664"/>
                    <measurement group_id="O3" value="2506.19" spread="314.555"/>
                    <measurement group_id="O4" value="3326.93" spread="631.053"/>
                    <measurement group_id="O5" value="178.90" spread="136.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="280"/>
                    <count group_id="O2" value="2924"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.96" spread="0.422"/>
                    <measurement group_id="O2" value="20.00" spread="0.000"/>
                    <measurement group_id="O3" value="30.00" spread="0.000"/>
                    <measurement group_id="O4" value="40.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Drug Exposure for Overall - Daily Dose</title>
        <description>Daily dose was calculated by total dose divided by the total days of receiving atorvastatin.</description>
        <time_frame>Day 1 to Week 12</time_frame>
        <population>The analysis set included all participants who received at least 1 dose of atorvastatin and evaluable for specified category (daily dose).</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin Unknown Dosage</title>
            <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Drug Exposure for Overall - Daily Dose</title>
          <description>Daily dose was calculated by total dose divided by the total days of receiving atorvastatin.</description>
          <population>The analysis set included all participants who received at least 1 dose of atorvastatin and evaluable for specified category (daily dose).</population>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="845"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.43" spread="1.633"/>
                    <measurement group_id="O2" value="20.00" spread="0.423"/>
                    <measurement group_id="O3" value="29.00" spread="2.646"/>
                    <measurement group_id="O4" value="39.96" spread="0.314"/>
                    <measurement group_id="O5" value="20.09" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Drug Exposure Within Each CVD Risk Group - Total Dose and Week 12 Dose</title>
        <description>Atorvastatin total dose: calculated from Day 1 to Week 12 or last dose; Week 12 dose: dose taken at Week 12 according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
        <time_frame>Day 1 to Week 12</time_frame>
        <population>The analysis set included all participants who received at least 1 dose of atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Drug Exposure Within Each CVD Risk Group - Total Dose and Week 12 Dose</title>
          <description>Atorvastatin total dose: calculated from Day 1 to Week 12 or last dose; Week 12 dose: dose taken at Week 12 according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
          <population>The analysis set included all participants who received at least 1 dose of atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total dose (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="975.00" spread="312.567"/>
                    <measurement group_id="O2" value="1760.84" spread="449.801"/>
                    <measurement group_id="O3" value="2790.00" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="3456.00" spread="1245.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total dose (Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="914.47" spread="224.965"/>
                    <measurement group_id="O2" value="1781.18" spread="415.197"/>
                    <measurement group_id="O3" value="2542.50" spread="261.964"/>
                    <measurement group_id="O4" value="3524.44" spread="464.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total dose (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="964.63" spread="254.036"/>
                    <measurement group_id="O2" value="1842.03" spread="383.312"/>
                    <measurement group_id="O3" value="2419.23" spread="342.332"/>
                    <measurement group_id="O4" value="3525.95" spread="373.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total dose (Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="964.04" spread="152.396"/>
                    <measurement group_id="O2" value="1804.61" spread="328.691"/>
                    <measurement group_id="O3" value="2740.00" spread="96.437"/>
                    <measurement group_id="O4" value="3131.20" spread="685.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 dose (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="252"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="0.000"/>
                    <measurement group_id="O2" value="20.00" spread="0.000"/>
                    <measurement group_id="O3" value="30.00" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="40.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 dose(Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="266"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="0.000"/>
                    <measurement group_id="O2" value="20.00" spread="0.000"/>
                    <measurement group_id="O3" value="30.00" spread="0.000"/>
                    <measurement group_id="O4" value="40.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 dose (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="1419"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.39" spread="1.678"/>
                    <measurement group_id="O2" value="20.00" spread="0.508"/>
                    <measurement group_id="O3" value="28.38" spread="3.254"/>
                    <measurement group_id="O4" value="39.97" spread="0.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 dose (Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="987"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="0.000"/>
                    <measurement group_id="O2" value="20.00" spread="0.000"/>
                    <measurement group_id="O3" value="30.00" spread="0.000"/>
                    <measurement group_id="O4" value="40.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Drug Exposure Within Each CVD Risk Group -Daily Dose</title>
        <description>Daily dose was calculated by total dose divided by the total days of receiving atorvastatin according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
        <time_frame>Day 1 to Week 12</time_frame>
        <population>The analysis set included all participants who received at least 1 dose of atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Drug Exposure Within Each CVD Risk Group -Daily Dose</title>
          <description>Daily dose was calculated by total dose divided by the total days of receiving atorvastatin according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
          <population>The analysis set included all participants who received at least 1 dose of atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Daily dose (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.81" spread="1.721"/>
                    <measurement group_id="O2" value="20.00" spread="0.000"/>
                    <measurement group_id="O3" value="30.00" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="40.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily dose (Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.53" spread="1.572"/>
                    <measurement group_id="O2" value="20.03" spread="0.719"/>
                    <measurement group_id="O3" value="30.00" spread="0.000"/>
                    <measurement group_id="O4" value="40.00" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily dose (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.39" spread="1.678"/>
                    <measurement group_id="O2" value="20.00" spread="0.508"/>
                    <measurement group_id="O3" value="28.38" spread="3.254"/>
                    <measurement group_id="O4" value="39.97" spread="0.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily dose (Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.29" spread="1.486"/>
                    <measurement group_id="O2" value="20.00" spread="0.136"/>
                    <measurement group_id="O3" value="30.00" spread="0.000"/>
                    <measurement group_id="O4" value="39.94" spread="0.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-related) for Overall</title>
        <description>All causalities adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage; Treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage.</description>
        <time_frame>Baseline to Week 12 (±28 days) or any unplanned visit (if occurred: any date during Week 4 to Week 16 )</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin Unknown Dosage</title>
            <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-related) for Overall</title>
          <description>All causalities adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage; Treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="1055"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All causalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="241"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-related) by Dose Group Within Each CVD Risk Level</title>
        <description>All causalities adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage; Treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage. The AEs were categorized by the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
        <time_frame>Baseline to Week 12 (±28 days) or any unplanned visit (if occurred: any date during Week 4 to Week 16 )</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-related) by Dose Group Within Each CVD Risk Level</title>
          <description>All causalities adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage; Treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; The event has a causal relationship with the treatment or usage. The AEs were categorized by the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All causalities (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All causalities (Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All causalities (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All causalities (Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related (Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related (Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events of Special Interest (AESI) for Overall</title>
        <description>AESI were categorized as muscle symptoms: myalgia, fatigue, weakness, creatine kinase (CK) values 10 times the upper limit of normal, or rhabdomyolysis, and muscle damage based on significant elevated CK; major cardiovascular events: myocardial infarction, stroke, unstable angina requiring re-hospitalization, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting; Death.</description>
        <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred:any date during Week 4 to Week 16)</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin Unknown Dosage</title>
            <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events of Special Interest (AESI) for Overall</title>
          <description>AESI were categorized as muscle symptoms: myalgia, fatigue, weakness, creatine kinase (CK) values 10 times the upper limit of normal, or rhabdomyolysis, and muscle damage based on significant elevated CK; major cardiovascular events: myocardial infarction, stroke, unstable angina requiring re-hospitalization, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting; Death.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="1055"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events of Special Interest (AESI) by Dose Group Within Each CVD Risk Level</title>
        <description>AESI were categorized as muscle symptoms: myalgia, fatigue, weakness, creatine kinase (CK) values 10 times the upper limit of normal, or rhabdomyolysis, and muscle damage based on significant elevated CK; major cardiovascular events: myocardial infarction, stroke, unstable angina requiring re-hospitalization, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting; Death according to the CVD risk stratification. Low-risk: 10 years CV risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
        <time_frame>Baseline (Day 1) to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events of Special Interest (AESI) by Dose Group Within Each CVD Risk Level</title>
          <description>AESI were categorized as muscle symptoms: myalgia, fatigue, weakness, creatine kinase (CK) values 10 times the upper limit of normal, or rhabdomyolysis, and muscle damage based on significant elevated CK; major cardiovascular events: myocardial infarction, stroke, unstable angina requiring re-hospitalization, revascularization with either percutaneous coronary intervention or coronary-artery bypass grafting; Death according to the CVD risk stratification. Low-risk: 10 years CV risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very high risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Elevated Abnormal Laboratory in Creatine Kinanse (CK), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) for Overall</title>
        <description>The elevated abnormal laboratory data was summarized: significant elevated CK: CK values 10 times the upper limit of normal; Persistent elevation in alanine aminotransferase, aspartate aminotransferase, or both: 2 consecutive measurements obtained 4 to 10 days apart that was more than 3 times the upper limit of the normal range.</description>
        <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin Unknown Dosage</title>
            <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Elevated Abnormal Laboratory in Creatine Kinanse (CK), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) for Overall</title>
          <description>The elevated abnormal laboratory data was summarized: significant elevated CK: CK values 10 times the upper limit of normal; Persistent elevation in alanine aminotransferase, aspartate aminotransferase, or both: 2 consecutive measurements obtained 4 to 10 days apart that was more than 3 times the upper limit of the normal range.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="1055"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT＞3*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST＞3*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK ＞= 10*ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Elevated Abnormal Laboratory in CK, ALT and AST by Dose Group Within Each CVD Risk</title>
        <description>The elevated abnormal laboratory data was summarized: significant elevated CK: CK values 10 times the upper limit of normal; Persistent elevation in alanine aminotransferase, aspartate aminotransferase, or both: 2 consecutive measurements obtained 4 to 10 days apart that was more than 3 times the upper limit of the normal range according to the CVD risk stratification. Low-risk: 10 years CV risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
        <time_frame>Baseline to Week 12 (±28 days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Elevated Abnormal Laboratory in CK, ALT and AST by Dose Group Within Each CVD Risk</title>
          <description>The elevated abnormal laboratory data was summarized: significant elevated CK: CK values 10 times the upper limit of normal; Persistent elevation in alanine aminotransferase, aspartate aminotransferase, or both: 2 consecutive measurements obtained 4 to 10 days apart that was more than 3 times the upper limit of the normal range according to the CVD risk stratification. Low-risk: 10 years CV risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT＞3*ULN (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT＞3*ULN (Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT＞3*ULN (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT＞3*ULN (Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST＞3*ULN (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST＞3*ULN (Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST＞3*ULN (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST＞3*ULN (Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK &gt;= 10*ULN (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK &gt;= 10*ULN (Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK &gt;= 10*ULN (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK &gt;= 10*ULN (Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Clinical Laboratory Overall- ALT and AST</title>
        <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for ALT and AST date were reported.</description>
        <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin Unknown Dosage</title>
            <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Clinical Laboratory Overall- ALT and AST</title>
          <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for ALT and AST date were reported.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="1055"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="1408"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="25.362"/>
                    <measurement group_id="O2" value="1.60" spread="27.048"/>
                    <measurement group_id="O3" value="1.40" spread="8.414"/>
                    <measurement group_id="O4" value="-0.25" spread="14.079"/>
                    <measurement group_id="O5" value="-1.00" spread="21.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT-Unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="239"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="11.639"/>
                    <measurement group_id="O2" value="2.25" spread="17.861"/>
                    <measurement group_id="O3" value="5.00" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="-20.70" spread="30.772"/>
                    <measurement group_id="O5" value="1.22" spread="13.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST- week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="1396"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="18.833"/>
                    <measurement group_id="O2" value="-5.54" spread="47.298"/>
                    <measurement group_id="O3" value="3.60" spread="2.966"/>
                    <measurement group_id="O4" value="-37.78" spread="87.382"/>
                    <measurement group_id="O5" value="-17.48" spread="61.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST- unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="224"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="6.605"/>
                    <measurement group_id="O2" value="-8.43" spread="58.715"/>
                    <measurement group_id="O3" value="9.00" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="-125.5" spread="184.247"/>
                    <measurement group_id="O5" value="2.22" spread="10.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Clinical Laboratory Overall- Bilirubin, Blood Urea Nitrogen, Cholesterol, Creatinine, Triglycerides, Uric Acid</title>
        <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline for bilirubin, blood urea nitrogen, cholesterol (total), creatinine, triglycerides, uric acid data were reported.</description>
        <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin Unknown Dosage</title>
            <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Clinical Laboratory Overall- Bilirubin, Blood Urea Nitrogen, Cholesterol, Creatinine, Triglycerides, Uric Acid</title>
          <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline for bilirubin, blood urea nitrogen, cholesterol (total), creatinine, triglycerides, uric acid data were reported.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="1055"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="1381"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.248"/>
                    <measurement group_id="O2" value="0.02" spread="0.323"/>
                    <measurement group_id="O3" value="-0.01" spread="0.132"/>
                    <measurement group_id="O4" value="0.00" spread="0.301"/>
                    <measurement group_id="O5" value="-0.08" spread="0.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin-Unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="236"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.301"/>
                    <measurement group_id="O2" value="0.04" spread="0.293"/>
                    <measurement group_id="O3" value="0.08" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="-0.36" spread="0.190"/>
                    <measurement group_id="O5" value="0.09" spread="0.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="1366"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="57"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="5.238"/>
                    <measurement group_id="O2" value="0.10" spread="5.001"/>
                    <measurement group_id="O3" value="-1.18" spread="2.989"/>
                    <measurement group_id="O4" value="-0.29" spread="4.417"/>
                    <measurement group_id="O5" value="-0.86" spread="9.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="216"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="3.495"/>
                    <measurement group_id="O2" value="-0.08" spread="5.326"/>
                    <measurement group_id="O3" value="3.11" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="4.66" spread="7.005"/>
                    <measurement group_id="O5" value="-1.16" spread="3.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol- week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="1417"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.13" spread="44.751"/>
                    <measurement group_id="O2" value="-45.15" spread="393.221"/>
                    <measurement group_id="O3" value="-40.35" spread="44.527"/>
                    <measurement group_id="O4" value="-36.98" spread="54.175"/>
                    <measurement group_id="O5" value="-27.20" spread="38.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="248"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.38" spread="31.472"/>
                    <measurement group_id="O2" value="-55.38" spread="41.996"/>
                    <measurement group_id="O3" value="-37.84" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="-75.98" spread="56.967"/>
                    <measurement group_id="O5" value="-24.23" spread="22.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="1366"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="57"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.202"/>
                    <measurement group_id="O2" value="0.01" spread="0.224"/>
                    <measurement group_id="O3" value="-0.09" spread="0.158"/>
                    <measurement group_id="O4" value="0.00" spread="0.106"/>
                    <measurement group_id="O5" value="0.01" spread="0.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine- unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="217"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.087"/>
                    <measurement group_id="O2" value="0.01" spread="0.130"/>
                    <measurement group_id="O3" value="0.01" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="0.09" spread="0.060"/>
                    <measurement group_id="O5" value="-0.05" spread="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="1416"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.95" spread="93.668"/>
                    <measurement group_id="O2" value="-27.88" spread="108.151"/>
                    <measurement group_id="O3" value="-83.19" spread="151.512"/>
                    <measurement group_id="O4" value="-20.97" spread="160.296"/>
                    <measurement group_id="O5" value="8.22" spread="49.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides- unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="248"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.84" spread="67.068"/>
                    <measurement group_id="O2" value="-46.19" spread="144.402"/>
                    <measurement group_id="O3" value="-100.9" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="-75.93" spread="88.578"/>
                    <measurement group_id="O5" value="-25.67" spread="39.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                    <count group_id="O2" value="1344"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="56"/>
                    <count group_id="O5" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.83" spread="621.039"/>
                    <measurement group_id="O2" value="-0.08" spread="1.438"/>
                    <measurement group_id="O3" value="-0.07" spread="0.795"/>
                    <measurement group_id="O4" value="-0.20" spread="1.468"/>
                    <measurement group_id="O5" value="-0.04" spread="1.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.859"/>
                    <measurement group_id="O2" value="0.12" spread="1.159"/>
                    <measurement group_id="O3" value="-0.30" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="0.68" spread="1.526"/>
                    <measurement group_id="O5" value="-0.28" spread="0.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Clinical Laboratory Overall- Creatine Kinase</title>
        <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for creatine kinase was reported.</description>
        <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin Unknown Dosage</title>
            <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Clinical Laboratory Overall- Creatine Kinase</title>
          <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for creatine kinase was reported.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="1055"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="1264"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.77" spread="168.370"/>
                    <measurement group_id="O2" value="-30.49" spread="388.838"/>
                    <measurement group_id="O3" value="-7.60" spread="24.572"/>
                    <measurement group_id="O4" value="-300.8" spread="698.733"/>
                    <measurement group_id="O5" value="-139.0" spread="431.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="169"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.65" spread="59.880"/>
                    <measurement group_id="O2" value="-26.74" spread="256.628"/>
                    <measurement group_id="O3" value="22.00" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O4" value="-335.2" spread="469.795"/>
                    <measurement group_id="O5" value="23.67" spread="27.609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Clinical Laboratory by Dose Group Within Each CVD Risk Level-ALT and AST</title>
        <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for ALT and AST date were reported according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
        <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred:any date during Week 4 to Week 16)</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Clinical Laboratory by Dose Group Within Each CVD Risk Level-ALT and AST</title>
          <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for ALT and AST date were reported according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT (Low risk)- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="126"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="14.557"/>
                    <measurement group_id="O2" value="1.68" spread="11.964"/>
                    <measurement group_id="O4" value="4.00" spread="15.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (Low risk)- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.80" spread="7.463"/>
                    <measurement group_id="O2" value="2.21" spread="15.514"/>
                    <measurement group_id="O4" value="-29.23" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (moderate risk)- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.68" spread="15.438"/>
                    <measurement group_id="O2" value="0.83" spread="19.970"/>
                    <measurement group_id="O4" value="0.77" spread="6.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (moderate risk)- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="17.146"/>
                    <measurement group_id="O2" value="-2.40" spread="16.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (high risk)- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="711"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.27" spread="14.774"/>
                    <measurement group_id="O2" value="3.10" spread="31.018"/>
                    <measurement group_id="O3" value="1.40" spread="8.414"/>
                    <measurement group_id="O4" value="5.79" spread="11.825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (high risk)- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="12.118"/>
                    <measurement group_id="O2" value="4.02" spread="12.412"/>
                    <measurement group_id="O3" value="5.00" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT(very high risk)- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="429"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.98" spread="56.864"/>
                    <measurement group_id="O2" value="-0.66" spread="25.035"/>
                    <measurement group_id="O4" value="-7.36" spread="15.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT(very high risk)- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="8.382"/>
                    <measurement group_id="O2" value="1.14" spread="24.172"/>
                    <measurement group_id="O4" value="-17.86" spread="37.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (low risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="126"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="9.684"/>
                    <measurement group_id="O2" value="0.76" spread="7.857"/>
                    <measurement group_id="O4" value="2.50" spread="7.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (low risk)- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="2.915"/>
                    <measurement group_id="O2" value="-0.28" spread="6.874"/>
                    <measurement group_id="O4" value="-8.56" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (moderate risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.36" spread="16.276"/>
                    <measurement group_id="O2" value="-1.49" spread="20.569"/>
                    <measurement group_id="O4" value="-30.51" spread="92.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (moderate risk)-unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="13.828"/>
                    <measurement group_id="O2" value="-1.66" spread="5.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (high risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="708"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="13.031"/>
                    <measurement group_id="O2" value="-0.21" spread="21.587"/>
                    <measurement group_id="O3" value="3.60" spread="2.966"/>
                    <measurement group_id="O4" value="1.38" spread="7.432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (high risk)-unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="5.299"/>
                    <measurement group_id="O2" value="0.79" spread="12.214"/>
                    <measurement group_id="O3" value="9.00" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (very high risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="420"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.62" spread="38.588"/>
                    <measurement group_id="O2" value="-17.79" spread="79.278"/>
                    <measurement group_id="O4" value="-85.34" spread="111.577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (very high risk)-unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="3.862"/>
                    <measurement group_id="O2" value="-30.13" spread="106.059"/>
                    <measurement group_id="O4" value="-164.5" spread="204.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Clinical Laboratory by Dose Group Within Each CVD Risk Level- Bilirubin, Blood Urea Nitrogen, Cholesterol, Creatinine, Triglycerides, Uric Acid</title>
        <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline for bilirubin, blood urea nitrogen, cholesterol (total), creatinine, triglycerides, uric acid data were reported according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
        <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Clinical Laboratory by Dose Group Within Each CVD Risk Level- Bilirubin, Blood Urea Nitrogen, Cholesterol, Creatinine, Triglycerides, Uric Acid</title>
          <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from baseline for bilirubin, blood urea nitrogen, cholesterol (total), creatinine, triglycerides, uric acid data were reported according to the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin (low risk)- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="122"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.237"/>
                    <measurement group_id="O2" value="-0.03" spread="0.270"/>
                    <measurement group_id="O4" value="0.07" spread="0.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (low risk)- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.236"/>
                    <measurement group_id="O2" value="0.08" spread="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (moderate risk)- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="139"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.191"/>
                    <measurement group_id="O2" value="0.01" spread="0.305"/>
                    <measurement group_id="O4" value="-0.09" spread="0.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (moderate risk)- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.237"/>
                    <measurement group_id="O2" value="0.01" spread="0.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (high risk)- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="696"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.271"/>
                    <measurement group_id="O2" value="0.03" spread="0.333"/>
                    <measurement group_id="O3" value="-0.01" spread="0.132"/>
                    <measurement group_id="O4" value="-0.04" spread="0.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (high risk)- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.294"/>
                    <measurement group_id="O2" value="-0.01" spread="0.273"/>
                    <measurement group_id="O3" value="0.08" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (very high risk)- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="424"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.209"/>
                    <measurement group_id="O2" value="0.02" spread="0.324"/>
                    <measurement group_id="O4" value="0.06" spread="0.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (very high risk)- unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.457"/>
                    <measurement group_id="O2" value="0.09" spread="0.350"/>
                    <measurement group_id="O4" value="-0.36" spread="0.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen(low risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="3.499"/>
                    <measurement group_id="O2" value="0.24" spread="2.990"/>
                    <measurement group_id="O4" value="-2.38" spread="3.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen(low risk)-unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.783"/>
                    <measurement group_id="O2" value="-0.98" spread="4.594"/>
                    <measurement group_id="O4" value="-3.67" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen(moderate risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="6.721"/>
                    <measurement group_id="O2" value="-0.14" spread="3.887"/>
                    <measurement group_id="O4" value="1.56" spread="4.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen(moderate risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="2.386"/>
                    <measurement group_id="O2" value="1.91" spread="2.925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen(high risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="694"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="5.191"/>
                    <measurement group_id="O2" value="0.20" spread="4.841"/>
                    <measurement group_id="O3" value="-1.18" spread="2.989"/>
                    <measurement group_id="O4" value="-0.99" spread="3.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen(high risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="4.248"/>
                    <measurement group_id="O2" value="-0.36" spread="5.678"/>
                    <measurement group_id="O3" value="3.11" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cholesterol (low risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.68" spread="46.926"/>
                    <measurement group_id="O2" value="-47.63" spread="56.296"/>
                    <measurement group_id="O4" value="-94.98" spread="71.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cholesterol (low risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.41" spread="28.986"/>
                    <measurement group_id="O2" value="-70.43" spread="46.727"/>
                    <measurement group_id="O4" value="-122.8" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cholesterol (moderate risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.71" spread="41.919"/>
                    <measurement group_id="O2" value="-43.23" spread="49.231"/>
                    <measurement group_id="O4" value="-5.28" spread="61.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cholesterol (moderate risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.59" spread="48.524"/>
                    <measurement group_id="O2" value="-81.23" spread="42.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cholesterol (high risk)-week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="713"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.72" spread="44.199"/>
                    <measurement group_id="O2" value="-56.65" spread="551.937"/>
                    <measurement group_id="O3" value="-40.35" spread="44.527"/>
                    <measurement group_id="O4" value="-38.43" spread="49.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cholesterol (high risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="114"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.78" spread="32.877"/>
                    <measurement group_id="O2" value="-56.26" spread="39.587"/>
                    <measurement group_id="O3" value="-37.84" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cholesterol (very high risk)-week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="426"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="31.528"/>
                    <measurement group_id="O2" value="-25.78" spread="49.060"/>
                    <measurement group_id="O4" value="-43.16" spread="51.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cholesterol (very high risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.96" spread="15.081"/>
                    <measurement group_id="O2" value="-40.75" spread="37.827"/>
                    <measurement group_id="O4" value="-64.29" spread="58.435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatinine (low risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.119"/>
                    <measurement group_id="O2" value="-0.01" spread="0.306"/>
                    <measurement group_id="O4" value="0.01" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatinine (low risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.067"/>
                    <measurement group_id="O2" value="0.01" spread="0.146"/>
                    <measurement group_id="O4" value="0.14" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatinine (moderate risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.299"/>
                    <measurement group_id="O2" value="0.00" spread="0.108"/>
                    <measurement group_id="O4" value="-0.05" spread="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatinine (moderate risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.089"/>
                    <measurement group_id="O2" value="-0.01" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatinine (high risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="694"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.175"/>
                    <measurement group_id="O2" value="0.01" spread="0.201"/>
                    <measurement group_id="O3" value="-0.09" spread="0.158"/>
                    <measurement group_id="O4" value="0.00" spread="0.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatinine (high risk)- unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.091"/>
                    <measurement group_id="O2" value="-0.01" spread="0.137"/>
                    <measurement group_id="O3" value="0.01" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatinine (very high risk)- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="415"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.200"/>
                    <measurement group_id="O2" value="0.01" spread="0.258"/>
                    <measurement group_id="O4" value="0.02" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatinine (very high risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.053"/>
                    <measurement group_id="O2" value="0.03" spread="0.119"/>
                    <measurement group_id="O4" value="0.08" spread="0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglycerides (low risk)- week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.48" spread="47.189"/>
                    <measurement group_id="O2" value="-31.41" spread="114.297"/>
                    <measurement group_id="O4" value="-14.16" spread="35.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglycerides (low risk)- unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.42" spread="28.999"/>
                    <measurement group_id="O2" value="-75.82" spread="101.162"/>
                    <measurement group_id="O4" value="-188.5" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglycerides (moderate risk)- week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="42.967"/>
                    <measurement group_id="O2" value="-22.32" spread="70.978"/>
                    <measurement group_id="O4" value="-18.19" spread="61.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglycerides (moderate risk)- unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.08" spread="14.674"/>
                    <measurement group_id="O2" value="-53.27" spread="61.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglycerides (high risk)- week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="713"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.70" spread="101.889"/>
                    <measurement group_id="O2" value="-29.87" spread="116.122"/>
                    <measurement group_id="O3" value="-83.19" spread="151.512"/>
                    <measurement group_id="O4" value="-46.98" spread="127.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglycerides (high risk)- unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="114"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.56" spread="70.510"/>
                    <measurement group_id="O2" value="-54.85" spread="189.895"/>
                    <measurement group_id="O3" value="-100.9" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglycerides (very high risk)- week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="425"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.34" spread="113.398"/>
                    <measurement group_id="O2" value="-25.34" spread="102.889"/>
                    <measurement group_id="O4" value="4.47" spread="217.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglycerides (very high risk)- unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.50" spread="89.174"/>
                    <measurement group_id="O2" value="-19.08" spread="85.039"/>
                    <measurement group_id="O4" value="-47.79" spread="71.981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>uric acid (low risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.838"/>
                    <measurement group_id="O2" value="-0.06" spread="0.980"/>
                    <measurement group_id="O4" value="0.32" spread="0.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>uric acid (low risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.337"/>
                    <measurement group_id="O2" value="0.23" spread="1.139"/>
                    <measurement group_id="O4" value="0.00" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>uric acid (moderate risk)-Week12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="2.753"/>
                    <measurement group_id="O2" value="-0.16" spread="1.335"/>
                    <measurement group_id="O4" value="-0.61" spread="1.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>uric acid (moderate risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.833"/>
                    <measurement group_id="O2" value="-0.47" spread="1.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>uric acid (high risk)-week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="683"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="1.875"/>
                    <measurement group_id="O2" value="-0.07" spread="1.447"/>
                    <measurement group_id="O3" value="-0.07" spread="0.795"/>
                    <measurement group_id="O4" value="-0.58" spread="1.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>uric acid (high risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.879"/>
                    <measurement group_id="O2" value="-0.16" spread="1.047"/>
                    <measurement group_id="O3" value="-0.30" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>uric acid (very high risk)-week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="403"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-407.9" spread="1732.170"/>
                    <measurement group_id="O2" value="-0.05" spread="1.568"/>
                    <measurement group_id="O4" value="0.32" spread="1.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>uric acid (very high risk)-unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="1.039"/>
                    <measurement group_id="O2" value="0.60" spread="1.051"/>
                    <measurement group_id="O4" value="0.90" spread="1.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen (Very high risk)- Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="414"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="4.794"/>
                    <measurement group_id="O2" value="-0.03" spread="5.975"/>
                    <measurement group_id="O4" value="-0.09" spread="5.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen (Very high risk)- unplanned</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="1.766"/>
                    <measurement group_id="O2" value="0.12" spread="5.484"/>
                    <measurement group_id="O4" value="7.43" spread="5.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Clinical Laboratory by Dose Group Within Each CVD Risk Level- Creatine Kinase</title>
        <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for creatine kinase was reported according to the CVD risk stratification. Low-risk: 10 years CV risk &lt;5%; Moderate-risk: 10 years CVD risk 5%~10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10%~15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
        <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Clinical Laboratory by Dose Group Within Each CVD Risk Level- Creatine Kinase</title>
          <description>The baseline data was collected within 1 month before taking atorvastatin or within 24 hours after starting atorvastatin. Change from Baseline for creatine kinase was reported according to the CVD risk stratification. Low-risk: 10 years CV risk &lt;5%; Moderate-risk: 10 years CVD risk 5%~10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CV risk 10%~15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatine Kinase(Low risk-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="116"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.40" spread="47.148"/>
                    <measurement group_id="O2" value="22.89" spread="135.208"/>
                    <measurement group_id="O4" value="15.75" spread="22.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase(Low risk-unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="16.793"/>
                    <measurement group_id="O2" value="29.41" spread="112.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase(moderate risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="126"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="46.688"/>
                    <measurement group_id="O2" value="0.03" spread="73.412"/>
                    <measurement group_id="O4" value="-363.4" spread="1078.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase(moderate risk)-unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="NA">1 participant of number analyzed</measurement>
                    <measurement group_id="O2" value="6.76" spread="30.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase(high risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="641"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.99" spread="118.333"/>
                    <measurement group_id="O2" value="14.49" spread="209.095"/>
                    <measurement group_id="O3" value="-7.60" spread="24.572"/>
                    <measurement group_id="O4" value="-0.25" spread="18.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase(high risk)-unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.96" spread="62.211"/>
                    <measurement group_id="O2" value="3.17" spread="87.977"/>
                    <measurement group_id="O3" value="22.00" spread="NA">1 participant of number analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase(very high risk)-Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="381"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-102.0" spread="387.028"/>
                    <measurement group_id="O2" value="-132.5" spread="637.616"/>
                    <measurement group_id="O4" value="-607.2" spread="800.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase(very high risk)-unplanned visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.50" spread="90.246"/>
                    <measurement group_id="O2" value="-134.0" spread="479.298"/>
                    <measurement group_id="O4" value="-335.2" spread="469.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Precentage of Participants With Discontinuation From the Study for Overall</title>
        <description>Percentage of participants who dropped out of the study and reasons for discontinuation were summarized overall.</description>
        <time_frame>12 weeks of follow-up</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O5">
            <title>Atorvastatin Unknown Dosage</title>
            <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
          </group>
        </group_list>
        <measure>
          <title>Precentage of Participants With Discontinuation From the Study for Overall</title>
          <description>Percentage of participants who dropped out of the study and reasons for discontinuation were summarized overall.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin. Number analyzed refers to number of participants evaluable for specified category.</population>
          <units>Percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="1055"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relation to study drug not defined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68"/>
                    <measurement group_id="O2" value="1.10"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.97"/>
                    <measurement group_id="O5" value="96.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.03"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Not related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Precentage of Participants With Discontinuation From the Study by Dose Group Within Each CVD Risk Level</title>
        <description>Percentage of participants who dropped out of the study and reasons for discontinuation were summarized by the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
        <time_frame>12 weeks of follow-up</time_frame>
        <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin &lt;=10 mg</title>
            <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 20 mg</title>
            <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 30 mg</title>
            <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
          </group>
          <group group_id="O4">
            <title>Atorvastatin 40 mg</title>
            <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
          </group>
        </group_list>
        <measure>
          <title>Precentage of Participants With Discontinuation From the Study by Dose Group Within Each CVD Risk Level</title>
          <description>Percentage of participants who dropped out of the study and reasons for discontinuation were summarized by the CVD risk stratification. Low-risk: 10 years CVD risk &lt;5%; Moderate-risk: 10 years CVD risk 5% to 10%; High-risk: Coronary Heart Disease (CHD) or CHD risk equivalents, or 10 years CVD risk 10% to 15%; Very-high risk: acute coronary syndromes, or ischemic cardiovascular disease combined with diabetes.</description>
          <population>The Safety Analysis population included all participants who received at least 1 dose of study drug atorvastatin and only counted the participants at the dose levels: ≤10 mg, 20 mg, 30 mg and 40 mg. &quot;Atorvastatin Unknown Dosage&quot; arm within each CVD risk level was exclude since incomplete information on medication.</population>
          <units>Percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="3080"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relation to study drug not defined (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.36"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related to study drug (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.36"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not related to study drug (Low risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="275"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relation to study drug not defined (Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="291"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.43"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related to study drug (Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not related to study drug (Moderate risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="287"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.06"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relation to study drug not defined (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14"/>
                    <measurement group_id="O2" value="1.07"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related to study drug (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not related to study drug (High risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="1491"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relation to study drug not defined(Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.97"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related to study drug (Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not related to study drug (Very high risk)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="1027"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Week 12 (±28 Days) or any unplanned visit (if occurred: any date during Week 4 to Week 16)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin &lt;=10 mg</title>
          <description>Participants received Atorvastatin &lt;=10 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin 20 mg</title>
          <description>Participants received Atorvastatin 20 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="E3">
          <title>Atorvastatin 30 mg</title>
          <description>Participants received Atorvastatin 30 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="E4">
          <title>Atorvastatin 40 mg</title>
          <description>Participants received Atorvastatin 40 mg daily according to doctor's prescription.</description>
        </group>
        <group group_id="E5">
          <title>Atorvastatin Unknown Dosage</title>
          <description>Participants didn’t complete dosing information including dosing page recording ‘NOT DONE’, or missing Week 12 dosing event, or records with missing stop date of dosing.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3080"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="3080"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Cardiac amyloidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Pelvic mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3080"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1055"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of the study are intrinsic to its observational, non-controlled, non-randomized design. This study stopped enrollment prior to meeting the planned sample size and was not committed to submit to China agency.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

